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SUMMARY
We present the case of a 21-month-old girl with two rare 
and life-threatening conditions, atypical haemolytic urae-
mic syndrome (aHUS) and haemophagocytic lymphohis-
tiocytosis (HLH), triggered by a cytomegalovirus (CMV) 
infection. Soon after admission, the girl became anuric 
and required continuous venovenous haemodiafiltration.
Initial treatments included methylprednisolone, 
fibrinogen and plasma infusion (for HLH), plasmapheresis 
(for thrombotic microangiopathy), immunoglobulins 
(for inflammation), ganciclovir (for CMV infection) 
and the antibiotic cefotaxime. On day 5, eculizumab 
(600 mg) was given for aHUS, with rapid improvement in 
haematological and nephrological parameters. Despite 
a subsequent isolated episode of right heart thrombosis 
that resolved with heparin treatment, the patient showed 
a favourable response to eculizumab (300 mg/15 days), 
with improved renal function, normal haematological 
values, and no treatment complications. In conclusion, 
eculizumab effectively treated aHUS in this case despite 
a comorbid immunological disease.
BACKGROUND
Atypical haemolytic uraemic syndrome (aHUS) 
accounts for 5%–10% of paediatric cases of HUS1 2 
and around 60% of patients with aHUS have an iden-
tified complement abnormality.3 In aHUS, uncon-
trolled complement activation causes thrombotic 
microangiopathy (TMA) which leads to multiorgan 
damage with significant morbidity and mortality.2 
Patients typically present with thrombocytopenia, 
Coombs negative microangiopathic haemolytic 
anaemia (MAHA) and acute renal failure.2 4 aHUS 
sometimes presents following an event causing 
complement amplification in combination with a 
genetic complement abnormality. Such events can 
be a common infection or, for example, malignancy, 
organ transplant or various drugs.2 4
Haemophagocytic lymphohistiocytosis (HLH) 
is a potentially life-threatening disorder charac-
terised by overwhelming immune activation and 
inflammation.5 Patients with HLH typically present 
with high-grade fever, progressive cytopenias, liver 
dysfunction and coagulopathy.6 HLH and aHUS 
are both rare conditions with distinct diagnostic 
criteria,2 4 5 their coexistence only reported previ-
ously in two cases.7 8
Eculizumab, a humanised anti-C5 monoclonal 
antibody, blocks the terminal complement pathway 
and is approved in many countries to treat aHUS. 
In prospective clinical trials, eculizumab inhibited 
TMA progression and prevented, or even reversed, 
organ damage.9 10 Rapid initiation of eculizumab 
treatment is beneficial as treatment delay can impair 
recovery of renal function.9 10 To our knowledge, 
we present the first published case of comorbid 
aHUS and HLH in which aHUS was treated with 
eculizumab. The case also reviews the diagnostic 
pathway to reach each individual diagnosis.
CASE PRESENTATION
A previously healthy 21-month-old girl presented 
with a 12-day history of fever and mild respiratory 
symptoms. Following presentation, her general 
condition worsened, with prostration, slight pallor 
of the skin and mucosa, and punctiform pete-
chiae on the lower extremities. Apart from a slight 
hepatomegaly, no organomegaly was observed.
INVESTIGATIONS
Initial investigations for influenza antigen and 
adenovirus in nasopharyngeal mucus were negative. 
Blood and urine cultures were negative, and chest 
X-ray was normal.
Blood tests revealed subnormal levels of 
haemoglobin (8.7 g/dL), haematocrit (28%), 
red blood cell (RBC) count (3.2×1012/L; 
normal range 3.9–5.2×1012/L), platelet count 
(139×109/L, decreasing to 98×109/L; normal 
range 150–450×109/L) and haptoglobin (3.2 g/L, 
decreasing to <0.06 g/L; normal range 0.3-2.0 g/L). 
Schistocytes were present, the direct Coombs test 
was negative, and lactate dehydrogenase (LDH) was 
elevated (3600 U/L; normal range 125-243 U/L). 
Creatinine was raised (4.5 mg/dL; normal range 
0.17-0.35mg/dL) and estimated glomerular filtra-
tion rate was 7 mL/min/1.73 m2 (normal  90mL/
min/1.73 m2). Urine biochemistry showed microhae-
maturia and proteinuria (100 mg/dL). The patient 
became anuric with severe proteinuria (1200 mg/
mmoL creatinine, normal range up to 22 mg/
mmoL) within the first few hours of hospitalisation, 
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indicating TMA and organ damage. Serum homocysteine 
(3.15 µmol/L; normal range <14 µmol/L) and methylmalonic 
acid (<0.05 µmol/L; normal range <0.5 µmol/L) levels were 
low.
Abdominal ultrasound revealed nephromegaly, with increased 
renal cortical echogenicity and normal arterial and venous flow 
in both kidneys; an echocardiogram was normal. Antinuclear 
antibodies were detected at a titre of 1/80 (speckled; normal 
limit <1:40); antimitochondrial antibodies, antigastric-mucosa 
antibodies, antismooth-muscle antibodies were all negative. 
Lymphocyte (4.07×103/µL; normal range 2.9-5.1×103/µL) and 
natural killer cell (115×106/L) counts were normal.
Laboratory results revealed high ferritin (4292 µg/L; normal 
range 12–156 µg/L) and triglyceride (2.5 mmoL/L; maximum 
8.14 mmoL/L (normal limit <1.65mmoL/L)) levels, and elevated 
D-dimer (5443 µg/L; normal limit <500 µg/L). Fibrinogen levels 
dropped from 3.9 g/L to 0.76 g/L (normal range 1.5–4 g/L) 
leading to suspicion of haemophagocytic syndrome.
DIFFERENTIAL DIAGNOSIS
When a child, without prior relevant medical history, presents 
with the classical features of TMA and renal failure, the most 
common cause would be Shiga toxin-producing Escherichia coli 
(STEC)-HUS. However, the rarer atypical form of HUS and 
thrombotic thrombocytopenic purpura (TTP) should also be 
considered.
In our patient, tests for classic, enterotoxigenic, enterohae-
morrhagic and enteroinvasive E. coli were negative. Although 
initial ADAMTS13 activity was borderline normal (≈10%), TTP 
was subsequently ruled out as ADAMTS13 activity increased to 
43% and then 108% at most recent follow-up, with no inhibi-
tors.
A differential diagnosis of either STEC-HUS, aHUS or TTP is 
important at an early stage due to different management strat-
egies for optimal outcome. Immunological tests demonstrated 
functional haemolytic activity (CH5066.9%), low C3 (58.8 mg/
dL, normal range 85-193) and normal C4 (19.0 mg/dL). Levels 
of complement factor (CF) H and CFI in plasma, and membrane 
cofactor protein (MCP) in peripheral blood lymphocytes, were 
normal. No anti-CFH antibodies were detected, and the CFH 
functional assay was negative. Low levels of homocysteine and 
methylmalonic acid excluded cobalamin C deficiency from the 
diagnosis.
A diagnosis of aHUS was made, based on normal ADAMTS13 
activity, no STEC, low homocysteine levels, low haptoglobin 
levels, elevated LDH, acute renal failure, the presence of throm-
bocytopenia, anaemia and schistocytes.
The presence of fever, hypofibrinogenaemia, hyperferriti-
naemia, hypertriglyceridaemia and bicytopenia also suggested 
haemophagocytic syndrome. Rapid diagnosis and prompt initia-
tion of treatment is essential for the survival of these patients. A 
diagnosis of HLH was made following the detection of increased 
soluble interleukin (IL) 2 receptor levels (4924 U/mL), hypercel-
lular bone marrow with polymorphic haematopoiesis and gran-
ulopoietic hyperplasia, and macrophages with haemophagocy-
tosis. Six of the eight criteria for a diagnosis of HLH established 
by the Histiocyte Society were met (at least 5 have to be met).5
TREATMENT
Fever and mild respiratory symptoms were treated with amoxi-
cillin prior to presentation.
Initial treatment comprised continuous venovenous haemodi-
afiltration (CVVHDF), RBC transfusion and empirical antibiotic 
coverage (cefotaxime). Cytomegalovirus (CMV) infection was 
detected by PCR and analysis of IgG (97.70 AU/mL) and posi-
tive IgM, and successfully treated with ganciclovir (5 mg/kg /
day). Ganciclovir was discontinued after 21 days and negative 
PCR results for CMV.
Initial TMA management involved two sessions of plasma-
pheresis, while for HLH management, four doses of fibrinogen 
were given with plasma infusion to address the hypofibrino-
genaemia, while a single dose of immunoglobulins (1 g/kg), and 
daily methylprednisolone (2 mg/kg) were administered to reduce 
inflammation.
Following confirmation of aHUS, eculizumab (600 mg) was 
initiated on the 5th day postadmission. The patient improved 
substantially, with haematologic al normalisation and clear 
nephrological improvement (figure 1). Four days later, the 
patient was haemodynamically stable with no neurological, 
respiratory or gastrointestinal symptoms. Renal replacement 
therapy (CVVHDF for 10 days and two haemodialysis sessions) 
was given for a total of 15 days postadmission.
Twenty-four hours later, however, she presented with right 
heart thrombosis (figure 2A) with ventricular and supraventric-
ular extrasystole. Platelets were 63×109/L, and D-dimer was 
45 446 µg/L. A two-way right femoral catheter was inserted, and 
clinical and sonographic progression with intravenous heparin 
treatment were highly satisfactory (figure 2B). There was no 
family history of thrombotic events, and thrombosis testing 
revealed no abnormalities. The patient received corticosteroids 
for 8 weeks, which were tapered until discontinuation. Hyper-
tension was managed with amlodipine, which was subsequently 
discontinued.
OUTCOME AND FOLLOW-UP
While genetic screening for complement mutations does not 
impact on immediate patient management, it does inform for 
long-term treatment decisions. A complete genetic workup 
revealed no genetic defects in CFH, CFHR1–5, C3, CFI, MCP, 
complement factor B (CFB), thrombomodulin, diacylglycerol 
kinase epsilon, complement factor properdin or ADAMTS13 
but a heterozygous risk haplotype was found in CFH (CFH-H3).
At most recent follow-up (June 2016) the patient remains 
healthy, without further complications, and with stable haema-
tological and renal parameters. The decision to discontinue 
eculizumab treatment, after more than 2 years, was based on the 
improved clinical status of the patient and the absence of identi-
fied pathogenic variants.
DISCUSSION
Our patient’s history suggests that both aHUS and HLH were 
triggered by CMV infection. Infectious events, particularly in the 
upper respiratory tract, are responsible for new TMA manifesta-
tions in 50%–80% of patients with aHUS,11–13 while infection—
notably herpesvirus infection—is one of the two most common 
settings for secondary HLH in children.5 14 aHUS was suggested 
in our patient by the combination of MAHA (negative Coombs 
test, schistocytes, increased LDH, low haptoglobin), throm-
bocytopenia and acute oligoanuric renal insufficiency. Initial 
ADAMTS13 measurement (∼10%) may suggest TTP, which, 
unlike aHUS, is typically associated with ADAMTS13 deficiency, 
however, the subsequent normalisation of ADAMTS13 ruled 
out TTP.15 16 aHUS is a rare disease that is complex to diag-
nose because of its heterogeneity. aHUS is a complement-me-
diated disease, yet 30%–50% of patients are diagnosed without 
an identified mutation, conversely incomplete penetrance of 
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complement gene mutations is 48%–64%.12 Similarly, normal 
C3 levels can be present in up to 70% of patients with aHUS as 
complement consumption occurs on the endothelial surface and 
not necessarily in plasma, making C3 an unreliable diagnostic 
criterion for aHUS.3 However, low C3 and normal C4 levels 
can be indicative of alternative pathway complement consump-
tion and lead to the clinical suspicion of complement-activated 
diseases like aHUS, even in patients with no identified comple-
ment abnormality. The number of complement mutations 
known to be associated with aHUS is increasing, indicating some 
of these patients may have an unknown mutation.1 4 Importantly, 
in case studies and prospective clinical trials, patients respond to 
eculizumab irrespective of mutation status.3 10
Diagnosing HLH can be difficult due to its rarity, variable 
presentation and the time needed to perform diagnostic tests for 
patients who often present in a critical condition. In our patient, 
six of the eight criteria for diagnosis of HLH were met based on 
the 2013 update of the Histiocyte Society 2004 guidelines.5 6 
These include presence of haemophagocytosis in bone marrow 
(in the absence of malignancy or other disorders), hyperfer-
ritinaemia (>500 µg/L), fever, cytopenia in up to two lineages, 
hypertriglyceridaemia and hypofibrinogenaemia, and soluble 
IL-2 receptor >2400 U/mL.
With the exception of Epstein-Barr virus-driven HLH, there 
are no specific management guidelines for infection-associ-
ated forms of HLH. Management of infection alone is often 
insufficient for clinical improvement. Some form of immu-
nosuppressive/immunomodulatory therapy might be neces-
sary to manage the hyperinflammatory state.14 We elected to 
manage with fibrinogen and administration of plasma given 
the hypofibrinogenaemia, as well as plasma exchange while 
HLH investigations were completed. Immunoglobulins at 1 g/
kg and methylprednisolone at 2 mg/kg/day were administered 
to reduce inflammation.
The cause of the serious cardiac thrombosis, which occurred 
10 days after admission, is unclear. Numerous interventions had 
been made prior to the thrombosis including administration 
of fibrinogen. aHUS may also be associated with the develop-
ment of thromboses due to endothelial damage.2 A single dose 
of eculizumab had been administered prior to the thrombosis; 
clinical trials of eculizumab have not reported an increased risk 
of clot formation.10 17
Only one prior paediatric case of comorbid aHUS and HLH 
has been described—an 8-year-old boy presenting with low 
C3 which was managed with plasma exchange, fresh frozen 
plasma, haemodialysis, erythrocyte transfusion and low-dose 
oral steroids.8 No information on ADAMTS13 levels or genetic/
functional analysis of complement regulatory proteins was 
reported, and the follow-up was only 45 days. An earlier paper 
described an 18-year-old girl with TMA (kidney biopsy) and 
haemophagocytic syndrome that were probably secondary to 
infection, although no causal agent was identified.7 Again, no 
ADAMTS13 levels or genetic/functional complement analysis 
were described, although the patient did have C3 hypocomple-
mentaemia, suggestive of complement upregulation. Treatment 
with RBC transfusion, methylprednisolone and immunoglobu-
lins was associated with no further disease manifestations over 
more than 3 years of follow-up.7 Neither of these cases was 
treated with eculizumab.
Our patient remained on eculizumab until June 2016 as the 
initial presentation was severe and the risk of further TMA mani-
festations was deemed too great to attempt discontinuation. 
Figure 1 Levels of (A) fibrinogen, ferritin and triglycerides, and (B) platelets, lactate dehydrogenase (LDH) and serum creatinine over the initial 
treatment period. CVVHDF, continuous venovenous haemodiafiltration.
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When evaluating eculizumab discontinuation we considered 
the clinical status of the patient and their individual risk 
benefit profile (including genetic analysis). The topic of eculi-
zumab discontinuation is important yet without consensus. A 
recent study stated that it is not yet clear whether patients with 
or without identified genetic mutations are at higher risk of 
new TMA manifestations when eculizumab is discontinued.18 
However, another suggests eculizumab discontinuation may 
be safer in patients with no documented complement gene 
variants after 6–12 months of treatment.19 Recommendations 
on treatment discontinuation may become clearer as this is 
tested in prospective studies and as evidence accumulates in 
the literature. At current evidence level the decision of length 
of eculizumab treatment is taken on a case-by-case basis. The 
decision on treatment strategy should consider the patient’s 
unique clinical situation, age, TMA and family history, as well 
as recognition of the complex and unpredictable nature of 
aHUS. If discontinuation of eculizumab is to be considered, 
the patient must: have been treated for a sufficiently long 
period to ensure maximal organ function recovery; be moni-
tored closely for signs and/or symptoms of TMA; and have 
immediate access to eculizumab so treatment can be restarted 
at the first signs and/or symptoms of TMA.
In conclusion, we report a rapid and favourable response to 
aHUS with eculizumab treatment in a patient with comorbid 
aHUS and HLH. Eculizumab was well tolerated and treatment 
was subsequently discontinued after more than 2 years of treat-
ment. The patient has suffered no further complications so far, 
but is closely monitored.
Learning points
 ► Eculizumab treatment led to an improvement in kidney 
function despite the presence of a comorbid immunological 
condition.
 ► Favourable renal recovery demonstrates the importance 
of rapid diagnosis and treatment of patients with atypical 
haemolytic uraemic syndrome (aHUS).
 ► Infections such as cytomegalovirus may unmask aHUS by 
activating the alternative complement pathway even in 
patients without an identified complement abnormality.
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